Industry
Biotechnology
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:16 am
Portfolio Pulse from Avi Kapoor
June 26, 2024 | 11:36 am
Portfolio Pulse from Avi Kapoor
June 17, 2024 | 11:41 am
Portfolio Pulse from Avi Kapoor
May 31, 2024 | 5:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 3:46 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 8:35 pm
Portfolio Pulse from Avi Kapoor
May 28, 2024 | 9:45 am
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 5:50 pm
Portfolio Pulse from Vandana Singh
May 21, 2024 | 6:39 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.